MedTrace Logo

Palonosetron Plus Aprepitant Versus Palonosetron in Preventing Nausea and Vomiting in Leukemic Patients

NCT02205164 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2014-07-31

No results posted yet for this study

Summary

The aim of present study is to evaluate if the addition of Aprepitant to multiple doses of palonosetron IV enhances the efficacy of multiple doses of palonosetron IV alone, in preventing CINV in AML or High risk MDS patient, treated with multiple days chemotherapy.

Conditions

  • Chemotherapy Induced Nausea and Vomiting

Interventions

DRUG

Palonosetron + Aprepitant

Aloxi 0.25mg Emend 125/80/80 mg

DRUG

Palonosetron

Aloxi 0.25mg

Sponsors & Collaborators

  • Associazione Salentina Angela Serra

    lead OTHER

Principal Investigators

  • Nicola Di Renzo, MD · Ospedale Vito Fazzi

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2014-08-31
Completion
2014-10-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02205164 on ClinicalTrials.gov